Search Results
Your search for 3 matches 15039 pages
Showing 9801 - 9850Ado-trastuzumab Emtansine vs Taxane in HER2-Positive Advanced Gastric Cancer
The adaptive phase II/III GATSBY trial has shown no survival difference between ado-trastuzumab emtansine (Kadcyla) vs taxane treatment in patients with previously treated locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Results were reported by Thuss-Patience et...
‘Non-Engineered’ T-Cell Therapy Produces Durable Responses in Hematologic Malignancies
Adoptive T-cell therapy using “non-engineered” T cells has been showing activity in hematologic malignancies, according to a presentation by Ann M. Leen, PhD, at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium.1 Dr. Leen is an immunologist and works at the Center for Cell and Gene Therapy,...
ASCO’s State of Cancer Care in America: 2017 Report Acknowledges Both the Progress Made in Oncology Care and the Challenges Ahead
Despite advances in cancer risk assessment, prevention, disease detection, drug development, and health-care delivery, which have led to unparalleled reductions in cancer incidence and mortality, access to affordable health care and increased administrative burdens placed on oncology practices...
Expert Point of View: Eloise Chapman-Davis, MD
Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...
Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer
Maintenance therapy with the tablet formulation of olaparib (Lynparza) significantly prolonged progression-free survival in patients with platinum-sensitive relapsed ovarian cancer and mutations in BRCA1/2 in the phase III SOLO2 trial, presented at the 2017 Society of Gynecologic Oncology (SGO)...
AACR 2017: Patients With Triple-Negative Breast Cancer Who Responded to Atezolizumab Had Long-Term Survival Benefit
Among patients with metastatic triple-negative breast cancer who were treated with the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq), those who responded to the treatment had a longer overall survival compared with those who did not respond, according to data...
AACR 2017: Combination of Nivolumab and Ipilimumab Improved Overall Survival in Advanced Melanoma
Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab, and appeared to have more favorable survival outcomes compared with those who received nivolumab, according to...
Survival in Advanced Melanoma With Ipilimumab at 10 mg/kg vs 3 mg/kg
In a phase III trial reported by Ascierto et al in The Lancet Oncology, treatment with ipilimumab (Yervoy) at 10 mg/kg vs 3 mg/kg resulted in improved overall survival in patients with advanced unresectable or metastatic melanoma. As noted by the investigators, although options for first-line...
Palbociclib Receives FDA Approval and Expanded Indication for First-Line Metastatic Breast Cancer
On March 31, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for a first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (Ibrance), based on the results from the confirmatory phase III trial PALOMA-2. The FDA action converts the...
AACR 2017: Combination HER2-Targeted Therapy Effective in Heavily Pretreated HER2-Positive Colorectal Cancer
A combination of two HER2-targeted therapies, trastuzumab (Herceptin) and lapatinib (Tykerb), showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results from the phase II HERACLES clinical trial, presented by Siena et al at the ...
AACR 2017: Addition of TTFields to Temozolomide Treatment Improves Survival for Patients With Glioblastoma
Patients with glioblastoma who wore a medical device that delivers alternating electrical fields in addition to being treated with the chemotherapeutic temozolomide had significantly improved median overall survival compared with those treated with temozolomide only, according to final results from ...
AACR 2017: Cancer Type and Mutation Identity Influenced Response to Neratinib in a Basket Clinical Trial
In the phase II SUMMIT clinical trial, the likelihood that a patient’s cancer responded to the investigational pan-HER–targeted therapeutic neratinib was influenced by both the cancer type and the identity of the gene mutation present in the cancer, according to results presented by...
Anti–Trop-2 Antibody Drug Conjugate in Heavily Pretreated Metastatic Triple-Negative Breast Cancer
As reported in the Journal of Clinical Oncology by Bardia et al, the anti–Trop-2 antibody drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily pretreated metastatic triple-negative breast cancer. Trop-2, a glycoprotein initially identified ...
Pembrolizumab in PD-L1–Positive Malignant Pleural Mesothelioma
In an interim analysis of the phase IB KEYNOTE-028 trial reported in The Lancet Oncology, Alley et al found that pembrolizumab (Keytruda) treatment produced durable responses in patients with malignant pleural mesothelioma. Study Details The current report involves 25 patients with previously...
Assessment of Immunohistochemistry Assays for PD-L1 Expression in NSCLC
In a study of four immunohistochemistry programmed cell death ligand 1 (PD-L1) expression assays registered with the U.S. Food and Drug Administration (FDA), scoring was highly concordant for expression in tumor cells but poorly concordant for scoring in immune cells in non–small cell lung...
Intestinal Microbiota and Relapse After Allogeneic Hematopoietic Cell Transplantation
A retrospective study has shown that the presence and abundance of a particular bacterial group in the intestinal microbiota are associated with a significantly lower risk of relapse or disease progression after allogeneic hematopoietic cell transplantation. The findings were reported by Peled et...
Interleukin-15 Levels Associated With Lymphoma Response to CAR T-Cell Treatment
As reported by Kochenderfer et al in the Journal of Clinical Oncology, remission in patients with advanced lymphoma induced by treatment with chimeric antigen receptor (CAR) T cells targeting CD19 (CAR-19) is associated with elevated serum interleukin-15 (IL-15) levels. Study Details The study...
Effect of Polypharmacy on Adherence to Adjuvant Endocrine Therapy for Breast Cancer
In a retrospective cohort study reported in the Journal of Oncology Practice, Calip et al found that polypharmacy overall was associated with increased adherence to adjuvant endocrine therapy for breast cancer. However, frequent use of some medication classes was associated with decreased...
3-Year Follow-up of Japanese Trial of Alectinib in ALK-Positive NSCLC
Promising 3-year outcomes were found in patients from a Japanese phase I/II study of alectinib (Alecensa) in previously treated patients with ALK-positive non–small cell lung cancer (NSCLC). The findings were reported by Tamura et al in the Journal of Clinical Oncology. Study Details In the ...
Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer
Hypofractionated radiotherapy was noninferior to standard radiotherapy in biochemical-clinical failure disease-free survival in men with localized prostate cancer, according to a study reported by Catton et al in the Journal of Clinical Oncology. Study Details In the trial, 1,206 patients with...
ASCO Launches Its New Journal Dedicated to Informatics
On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI). The first four articles published in JCO CCI are: 1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...
Major Pharmaceutical Companies Collaborate in NCCN Research Project
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-industry collaborative research project in which Boehringer Ingelheim and Eli Lilly are collaborating with NCCN to study combination therapeutic agents in ...
Future Perspectives in Geriatric Oncology: How the Young Can Care for the Old
In the upcoming decades, the number of older adults with cancer will drastically increase due to aging of Western societies.1 The risk of cancer strongly increases with age. Consequently, all future oncologists will be exposed to the challenges of caring for this heterogeneous population. Older...
Delays in Radiotherapy for Head and Neck Cancer in Insured and Indigent Populations
In a study reported in the Journal of Oncology Practice, Thomas et al found that interruption of radiotherapy for head and neck cancer was more frequent and treatment outcomes were poorer among indigent populations vs commercially or Medicare-insured populations within a single academic health...
Celecoxib or Celecoxib/Zoledronic Acid in Men Initiating Hormone Therapy for Prostate Cancer
As reported by Mason et al in the Journal of Clinical Oncology, long-term survival results of the UK-based, multiarm, multistage platform–design STAMPEDE trial showed no survival benefit with the addition of celecoxib or celecoxib plus zoledronic acid in men initiating long-term hormone...
Anne Friedman Glauber, Cofounder of Online Pancreatic Cancer Forum, Dies at Age 63
Anne Friedman Glauber, 63, co-founder of Let’s Win, an online community for persons affected by pancreatic cancer, recently passed away at her home in New York City, after a courageous battle with the disease. Ms. Glauber’s dedication to the organization (www.letswinpc.org) helped countless...
Intermittent Sunitinib in Metastatic Renal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Moshe C. Ornstein, MD, of Cleveland Clinic Taussig Cancer Institute, and colleagues found that an intermittent schedule of sunitinib (Sutent) may be feasible in patients with previously untreated metastatic renal cell carcinoma. In...
Potential Surrogate for All-Cause Mortality Risk in Localized Prostate Cancer
In a study reported in JAMA Oncology, Trevor J. Royce, MD, of Harvard Radiation Oncology Program, Brigham and Women’s Hospital, and colleagues found that a prostate-specific antigen (PSA) nadir > 0.5 ng/mL may be a dominant risk factor for all-cause mortality after radiation therapy and...
Reducing Debilitating Symptoms of Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Tamas Hickish, MD, of Poole Hospital NHS Foundation Trust, Dorset, England, and colleagues found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite ...
Examining the Impact of ‘Death With Dignity’ Legislation
Despite the controversy surrounding “Death With Dignity” laws, which allow physicians to prescribe life-ending drugs to terminally ill patients, they have a long history of majority support from Americans. According to a Gallup poll taken in 2015, nearly 7 in 10 Americans (68%) agreed that...
Acupuncture for the Management of Hot Flashes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...
Implications of SWOG S0777 and the Future of Combination Treatments for Multiple Myeloma
The treatment of multiple myeloma is becoming increasingly complicated. This is not only because of the complexity of the disease, but also because of the increasing number of effective combination treatments and continuous development of new drugs. This has resulted in an ever-increasing number ...
Adding Bortezomib to Lenalidomide/Dexamethasone Improves Survival in Patients With Newly Diagnosed Multiple Myeloma
In the phase III SWOG S0777 trial reported in The Lancet, Brian G.M. Durie, MD, of Cedars-Sinai Samuel Oschin Cancer Center, and colleagues found that adding bortezomib (Velcade) to lenalidomide (Revlimid)/dexamethasone improved progression-free and overall survival in patients with newly...
New First-Line Options for ALK-Positive Lung Cancer on the Horizon
Anaplastic lymphoma kinase (ALK) rearrangements define a subset of non–small cell lung cancer (NSCLC) patients for whom ALK inhibitors are highly effective. In PROFILE 1014, the multitargeted ALK inhibitor crizotinib (Xalkori) was shown to be superior to platinum/pemetrexed (Alimta) chemotherapy...
Markedly Improved Progression-Free Survival With First-Line Ceritinib vs Platinum Chemotherapy in ALK-Rearranged NSCLC
In the phase III ASCEND-4 trial reported in The Lancet, Jean-Charles Soria, MD, of Institut Gustave Roussy, and colleagues found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in the first-line treatment of advanced anaplastic lymphoma kinase...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
The Art of Medicine in the World of Evidence-Based Medicine
Christian Taverna, MD, a lymphoma specialist at the Hospital Münsterlingen in Switzerland, commented on this patient series for The ASCO Post. He noted that the Swiss Group for Clinical Cancer Research (SAKK) tried to address the question of the optimal duration of rituximab (Rituxan) maintenance...
For One Hematologist, No Disease Progressions in Follicular Lymphoma With Rituximab Maintenance
Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...
Plinabulin Improves Survival in Subset of Patients With Non–Small Cell Lung Cancer
The investigational small-molecule plinabulin yielded some interesting benefits when added to docetaxel in previously treated patients with stage III/IV non–small cell lung cancer (NSCLC), in a phase II study.1 Although the benefit of the doublet was modest in the overall study population, the...
IASLC Endorses Tobacco Reform Report Outlining Progress Toward Ending Adult Cigarette Smoking
The International Association for the Study of Lung Cancer (IASLC) has endorsed a report released by the Core Team for Tobacco Control that outlines key action items that can be taken immediately to accelerate progress toward ending cigarette smoking in adults. Issuing their Executive Summary ...
Making the Case for Sentinel Node Biopsy in Early Cancers of the Oral Cavity
“The majority of patients with oral cavity cancers will undergo an unnecessary operation,” Sandeep Samant, MD, stated at a session on managing N0 neck cancer at the 2016 Lurie Cancer Center Multidisciplinary Head & Neck Symposium in Chicago.1 That operation is elective neck dissection, and it ...
Online Symptom-Management Curriculum May Improve Depression and Fatigue in Breast Cancer Survivors
With thousands of devices to track and manage health and wellness, eHealth tools are beginning to transform modern health care and research, demonstrating quantifiable improvements in patient outcomes. According to the results of a randomized controlled trial (Reimagine), breast cancer survivors...
Expert Point of View: Milind Javle, MD
Milind Javle, MD, Professor of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, Houston, discussed the findings from the CheckMate 040 trial presented at the 2017 Gastrointestinal Cancers Symposium. There is a strong rationale for investigating immunotherapy in liver ...
Nivolumab Shows Benefit in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, treatment with nivolumab (Opdivo) resulted in responses and long-term survival in patients who were either previously treated or naive to sorafenib (Nexavar), CheckMate 040 has shown.1 Altogether 19% of patients responded to the antibody...
New Antiviral Agent May Prevent Posttransplant Cytomegalovirus Infections
Patients receiving the antiviral letermovir (MK-8228, AIC246), as compared to placebo, were almost twice as likely to avoid infection with cytomegalovirus or fail for other reasons in a randomized phase III international trial presented at the 2017 BMT Tandem Meetings, the joint meeting of the...
Novel Immunotherapeutic Vaccine Studied in Colorectal Cancer
Patients with advanced colorectal cancer mounted a robust response to an experimental vaccine and low-dose cyclophosphamide, and strong responses were associated with improvements in survival in a phase I/II clinical trial of modified vaccinia virus Ankara–5T4 (TroVax).1 Martin Scurr, PhD, of...
The Path Forward for Clinical Pathways in Oncology
The year 2016 was a memorable one for oncology. In January, President Barack Obama announced the launch of the National Cancer Moonshot initiative, spearheaded by Vice President Joe Biden, which aims to accelerate cancer research. And in December, through bipartisan Congressional support, the 21st ...
Active Surveillance Appears to Be Safe for Small Renal Masses
The prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry shows that over the intermediate term, active surveillance appears to be as safe as primary intervention for carefully selected, older, sicker patients with small renal masses.1 As the data mature,...
Expert Point of View: Ann W. Silk, MD
Ann W. Silk, MD, of Rutgers Cancer Institute of New Jersey, New Brunswick, presented the day’s highlights and commented that the study by Hellmann et al shows the utility, and, in fact, the necessity, of developing a new means of estimating outcomes for patients treated with immunotherapies....
Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests
Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.1 “In...
